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http://dx.doi.org/10.10quency in African-Americans, but yet an increased age-related prevalence of AD. An algorithm
for prevention clinical trials incorporating TOMM40’523 (Translocase of Outer Mitochondria Mem-
brane) and APOE depends on accurate TOMM40’523-APOE haplotypes.
Methods: We have compared the APOE and TOMM40’523 phased haplotype frequencies of a 9.5
kb TOMM40/APOE genomic region in West African, Caucasian, and African-American cohorts.
Results: African-American haplotype frequency scans of poly-T lengths connected in phase with
either APOE ε4 or APOE ε3 differ from both West Africans and Caucasians and represent admixture
of several distinct West African and Caucasian haplotypes. A new West African TOMM40’523
haplotype, with APOE ε4 connected to a short TOMM40’523 allele, is observed in African-
Americans but not Caucasians.
Conclusion: These data have therapeutic implications for the age of onset risk algorithm estimates
and the design of a prevention trial for African-Americans or other mixed ethnic populations.
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The apolipoprotein E4 (APOE ε4) allele frequency
among Africans and African-Americans with late-onset Alz-
heimer’s disease (LOAD) was lower than in Caucasians in
several early APOE ε4 studies [1–3]. The relationshipthor. Tel.: 919-271-4076.
len.roses@duke.edu
e Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/3.0/).
16/j.jalz.2014.06.009between APOE ε4 and the risk of LOAD in the Yoruban
population, one of the Nigerian ethnic groups, showed the
deleterious effect of APOE ε4, but the allele frequency of
APOE ε4 in the Yorubans was lower than in Caucasians
[1]. The lower APOE ε4 allele frequency in African-
Americans with LOAD, coupled with a similar or higher
incidence of dementia among African-Americans compared
with Caucasians, has remained an area of great interest and
discussion over the past two decades. These early studiesimer’s Association. This is an open access article under the CC BY-NC-ND
Fig. 1. Proportion of TOMM40’523 (Translocase of Outer Mitochondria
Membrane) short and long alleles connected to apolipoprotein E4 (APOE
ε4) chromosomes in a cohort of Ghanaian subjects compared with Cauca-
sian subjects. The proportion of short alleles connected to APOE ε4 as a
cis-haplotype in one of the two Caucasian discovery cohorts (“Canadian”)
was less than 2% (two alleles of.100 chromosomes) [8]. In the other cohort
(“Arizona”) there were no S alleles connected to APOE ε4, nor in other
Caucasian cohorts subsequently tested. A large proportion of S alleles
was attached to APOE ε4 chromosomes in a Ghanaian cohort tested for di-
versity in a series of ethnic cohorts [12]. These data formed the rationale for
testing African and African-American cohorts once the poly-T sequence
methodology allowed in-phase haplotyping and an accuracy of6 one base.
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gene may be operating in African-Americans [4,5]. This led
to several association studies of promoter polymorphisms,
which were noninformative [6,7].
The haplotype relationship between APOE ε4 and
TOMM40’523 (Translocase of Outer Mitochondria Mem-
brane) in an African-American cohort identified a distinct
difference in the frequency of APOE ε4 alleles in-phase
with a Short TOMM40’523 allele, a combination rarely
observed in Caucasian cohorts (Fig. 1). An early study of a
Ghanaian cohort found the allele frequency of APOE ε4 to
be less than Caucasians or African-Americans. However, a
significant proportion of APOE ε4 alleles was in phase
with Short TOMM40’523 alleles. This suggested the pres-
ence of a possible cross-over event occurring in the Ghana-
ians, a distinct observation in West Africans that has been
introduced in African-Americans and rarely observed in
Caucasian cohorts [1] (Fig. 1). Several nonphased associa-
tion studies of APOE regulatory region polymorphisms
were performed in Caucasians and were not informative to
the question of phased haplotypes in other ethnicities
[6,7]. This study emphasizes the role of individual risk
prediction for Mild Cognitive Impairment due to
Alzheimer’s Disease (MCI-AD) and/or LOAD based on
primary TOMM40’523 length differences and the presence
or absence of APOE ε2. Based on the comparison of allele
frequencies in Caucasians, West Africans, and African-
Americans reported in this communication, the conclusion
is that individual risk prediction based on a new in-phase
assay that directly determines haplotypes of TOMM40’523
and APOE, rather than imputing data based categorical
poly-T lengths (short-S, long-L, and very long-VL) to deter-
mine which TOMM40’523 poly-T lengths are linked
to APOE genotypes in other ethnicities which different
variations of lengths were observed. Studies to precisely
define a risk prediction algorithm for ethnicities other
than Caucasians based on accurate age of onset data and
TOMM40’523-APOE haplotypes are ongoing.2. Results
2.1. Background of prior results
We reported in 2010 that base length variation of a poly-T
tract (short sequence repeat (SSR), rs10524523;
TOMM40’523) in the translocase of outer mitochondrial
membrane 40 homolog (TOMM40) gene has been associated
with LOAD age of onset [8]. TOMM40 is adjacent to, and in
LD with, the APOE gene. With the use of phylogenetic map-
ping within the LD region containing the TOMM40 and
APOE genes, considerable progress has been made in
analyzing the role of genetics in LOAD. Rather than simply
observing APOE allele frequencies for this complex neuro-
logical disease, it became critically important to review the
data for haplotypes of TOMM40 and APOE to support Alz-
heimer’s disease clinical trials using pharmacogenetics, and
especially prevention studies using enrichment algorithms in
their design. TOMM40’523 length-sequence groups were
categorized as short (S: T  19), long (L:  20T  29), or
very long (VL: T  30). The TOMM40’523 genotypes are
informative for the LOAD age of onset for individuals
who carry all APOE genotypes, not just APOE ε4-bearing
genotypes: 97% of Caucasian individuals, unlike APOE
ε4-bearing genotypes which are informative in only 29%
of the population. If TOMM40’523 had been discovered
before the association of APOE ε4 and LOAD in 1993,
then TOMM40’523 would have been considered far more
informative for age of onset distributions due to the richness
of poly-T length variations at a single genetic locus
[rs10524523] [9]. Two frequent APOE genotypes, APOE
ε3/3, and APOE ε2/3, representing almost two-thirds of
the Caucasian population were uninformative for LOAD
risk using APOE ε4 carriage, but as TOMM40’523 genotyp-
ing includes all the APOE ε4 genotypes, the APOE ε3, and
APOE ε2 data are now also informative for risk [10] (Fig. 2).
Using phylogenetic analysis, we now recognize that
each copy of APOE ε3 (and APOE ε2) is attached on
the same chromosome (in phase) to either of two
TOMM40’523 allele sizes, S or VL, in Caucasians. The
distinction was clear and S and VL forms were each found
grouped separately within two major divergent phyloge-
netic clades. These data were used to describe the cate-
gories for simplicity [8,11]. This allows APOE ε3 to be
resolved into two APOE ε3 haplotypes: APOE ε3-S and
APOE ε3-VL. When observed as a genotype using these
haplotypes there are three distinct APOE ε3/3–
TOMM40’523 haplotypes (S/S, VL/VL, and S/VL),
each with a distinct age of onset distribution. APOE ε2
also is also attached to S or VL poly-T, lengths but pro-
vide a later age of onset for APOE ε2/3 patients as previ-
ously observed [10] (Fig. 1). APOE ε4 haplotypes account
for almost all Caucasian APOE ε4 carriage. There are six
different TOMM40’523 genotypes: APOE ε4/4 each have
as L/L genotype; for APOE ε3/4 there are two
TOMM40’523 genotypes with one allele of L and the
Fig. 2. Age at the onset of cognitive impairment as a function of
TOMM40’523 (Translocase of Outer Mitochondria Membrane) genotypes.
The Bryan Alzheimer’s Disease Research Center (ADRC)Memory, Health,
and Aging cohort (n 5 508, 106 conversion events) was followed prospec-
tively at the Bryan ADRC at Duke University. Cognitive Status was deter-
mined using standard neuropsychological tests. The age at which
cognitive impairment occurred was retrospectively stratified by
TOMM40’523 genotype, and Kaplan-Meier curves were constructed.
TOMM40’523 genotypes and the corresponding apolipoprotein E (APOE)
genotypes are indicated on the figure. The red line corresponds to APOE
ε4/4; the two green lines correspond to APOE ε3/4,and the three blue lines
correspond to APOE ε3/3. Note that within this cohort there were 78 indi-
viduals who carried an APOE ε2 allele, but only five developed cognitive
impairment during the study (VL/L (APOE ε2/4), n 5 1; S/L (APOE ε2/
4), n 5 2; VL/VL (APOE ε3/3), n 5 2). The data for these individuals
are indicated as points on the appropriate TOMM40 genotype curve; open
circles and filled diamonds indicate the age at onset of symptoms in the
APOE ε2/4 and APOE ε2/3 groups, respectively. The numbers of subjects
per TOMM40’523 genotype (number case to converted status) were L/L,
(APOE ε4/4) n 5 23 (11); VL/L (APOE ε3/4) n 5 54 (24); S/L(APOE
ε3/4) n 5 72(23); S/S(APOE ε3/3 or APOE ε3/2), n 5 100 (20); S/VL(A-
POE ε3/3 or APOE ε3/2) n 5 138(22); VL/VL(APOE ε3/3 or APOE ε3/
2), n 5 51 (9). Abbreviations: S, short; L, long; VL, very long.
Table 1
Caucasian TOMM40’523-APOE haplotypes and age at high risk used in
TOMMORROW trial
523 or APOE genotype Haplotype frequency Age at high risk
523 L/L 2% All high risk
523 L/VL 13% All high risk
APOE ε2/4 3% All high risk
523 S/L 14% 74
523 S/S 17% 77
523 S/VL 36% 76
523 VL/VL 18% All low risk
APOE ε2/2 1% All low risk
APOE ε2/3 13% All low risk
Abbreviations: APOE, apolipoprotein E; S, short; L, long; VL, very long;
TOMM40, Translocase of Outer Mitochondria Membrane.
NOTE. For the TOMMORROWStudy, all APOE ε2 carriers are assigned
to the high-risk or low-risk categories according to APOE genotype. Risk is
assessed for all other subjects according to the TOMM40 genotype. Subjects
with APOE ε2/2, APOE ε2/3, and VL/VL are considered to be at low risk.
Subjects with APOE ε2/2 and APOE ε2/4 do not have sufficient AD onset
data, but represent 3% of the population., APOE ε2/4 were classified as
high risk so that they would all be entered and randomized in the “high
risk” treatment or placebo groups. Certain genotypes are considered to be
high risk in the context of the targeted age range for the delay-of-onset clin-
ical trial. Subjects with any of three 523 genotypes, S/L, S/S, and S/VL, will
be placed in the high-risk category if the age at entry to the trial is greater
than the age indicated. The TOMM40’523 genotype frequencies are from
the Cache County Study ofMemory cohort (n5 2042). TheAPOE genotype
frequencies are those for Caucasian controls from the Farrer et al. meta-
analysis study (n 5 6262) [46].
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APOE ε3/4 genotypes: S/L or VL/L (Table 1 and
Fig. 2) [9]. Most Caucasians are APOE ε3/3 and there
are three possible TOMM40’523 genotypes: S/S, S/VL,
or VL/VL, each with a different age of onset distribution.
There are still too few APOE ε2/2 and APOE ε2/4 LOAD
subjects observed in prospective age of onset cohorts to
determine the accurate LOAD age of onset distributions
for these two uncommon genotypes, but APOE ε2/3 dis-
tributions are displaced to the right [older onset] with later
ages of onset due to the presence of an APOE ε2 allele
[10]. One important practical consequence of these find-
ings is that in planning LOAD prevention trials, it is
more informative to review the genotypic age of onset
data for the TOMM40’523-APOE haplotypes instead of
the current practice of simply observing APOE allele fre-
quencies for this complex neurological disease.
It became evident very early in the TOMM40’523
research that different ethnic groups have different haplo-
type frequency profiles of TOMM’523 poly-T lengthsthan those found in several geographical diverse Caucasian
cohorts [12] (Fig. 1). This manifests itself in several
different ways. One relates to the differences between the
lengths of poly-Ts attached to APOE ε4 or APOE ε3. The
second ethnic variation can be the presence of a different
haplotype not observed in Caucasians. Both of these differ-
ences will be presented in this communication regarding
highly variable inheritance from two different ethnicities
that are combined in African-Americans. The first type of
poly-T length heterogeneity is due to the fact the
TOMM40’523 poly-T occurs at a single locus but range
in length from 10 to 50 bases. A distinct and broader sets
of poly-T lengths characterizes many ethnic groups. The
second involves a unique TOMM40’523 combination not
observed in Caucasians, and one of these distinct haplo-
types is present in West Africans and transmitted to
African-Americans. The number of TOMM40’523 haplo-
types is far richer for generating genotype combination
than the two SNP loci defining APOE coding sequences
(at amino acid positions 112 and 152 of 299).2.2. New data
In this communication, we present new data for African-
American and West African populations. We examined
TOMM40’523 length distributions in African-Americans
and Yorubans (Figs. 1, 3, 4). We will demonstrate that
using a new phased sequencing method for APOE and
Fig. 3. Haplotypes of TOMM40’523 (Translocase of OuterMitochondriaMembrane) alleles connected to apolipoprotein E4 (APOE ε4). The length sizes of the
poly-Talleles are indicated in each of the panels: Panel A upper left: Caucasians; Panel B upper right, African-Americans; Panel C lower right, Yorubans (West
Africans), and Panel D lower left, Japanese. Note that the Caucasians in Panel A have two L poly-T groupings at T22 and T28/29. Yorubans in Panel C have three
groupings: two L groupings at T20-22 and T30-33, the second peak being slightly longer than in Caucasians. In addition there is a distinct peak at S-T15-16 not
observed in the Caucasians, In Panel B African-Americans carry the S poly-Ts at T13-16, like the Yorubans but rarely observed in Caucasians, In African-
Americans L poly-T lengths including T28-T34which includes the Caucasian contribution of T28-30 and the Yoruban contribution T30-33. Japanese are shown
to demonstrate that other ethnicities have characteristic patterns of poly-Ts connected to APOE ε4 and, in this group, only T26-28—a bit shorter than the Cauca-
sian long peak but with no T20-23. Abbreviations: S, short; L, long; VL, very long.
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Caucasian, Yoruban, and African-American populations,
it is possible to directly determine in-phase
TOMM40’523-APOE haplotypes that were previously not
possible to impute based on historical Caucasian data,
particularly where the TOMM40’523 lengths overlap in
the L–VL size transition. We have also demonstrated in
both West African cohorts that that there are a large pro-
portion of APOE ε4 alleles physically connected in-phase
to S alleles, which is extremely rare or non-existent for
Caucasians examined. There is now the opportunity to
assess whether the TOMM40’523 risk algorithm developed
for the TOMMORROWAD prevention trial can be gener-
alized for other ethnic groups using quantitative lengths
and distinct haplotypes [9].
In a previously reported study, we examined control
sets of Caucasians and Ghanaians with respect to APOE
and TOMM40 allele frequencies [12] (Fig. 1). At that
time the technique to perform phased haplotyping in this
region was not available, thus we had not been able to
accurately determine the proportion of TOMM40’523 al-
leles connected to APOE alleles [12]. The data were
generated using the categorical sizes for TOMM40’523
based on Caucasian classification. However, in Caucasians
98–100% of the TOMM40’523 L variants were APOE ε4-
connected and ,2% were connected to a S-TOMM40’523
poly-T. Nonphased sequencing of Ghanaians suggestedthat the S-TOMM40’523 alleles were connected to both
APOE ε4 and APOE ε3 alleles (Fig. 1). There was a strik-
ing proportion of APOE ε4 alleles linked to S
TOMM40’523 alleles observed in African-Americans but
not observed in Caucasians (Fig. 3). Confirmation experi-
ments were planned using publically available population
control samples from the Coriell Cell Repository to deter-
mine if the original Caucasian and Ghanaian data could be
replicated and to provide a standardized data set for other
investigators to confirm [12]. Fig. 3 compares the
TOMM40’523 genotypes from four defined ethnic groups:
Caucasian, Yoruban, and African-American; a fourth
ethnicity from Japan is also illustrated to further demon-
strate the differences in the relationship of APOE ε4 and
the two L-TOMM40’523 allele peaks in another ethnic
group [12]. In the Caucasian population (Fig. 3, Panel
A) the length of the TOMM40’523 alleles connected to
APOE ε4 is displayed, and do not differ from the other
normal Caucasian series previously published [8,13].
There are two distinct and separated TOMM40’523 L
peaks at L-T 5 22–23 and L-T28-29) in Caucasians
(only one in Japanese; Fig. 3, Panel A and D) S poly-T
lengths do not link with APOE ε4 alleles in Caucasians,
but there is a previously undetected overlap in length
with the smallest of the VL lengths observed in on
APOE ε3 and APOE ε2 strands that would be labeled L
in the convention used since 2010 (Fig. 3, Panel A). In
Fig. 4. Haplotypes of TOMM40’523 (Translocase of Outer Mitochondria Membrane) alleles connected to apolipoprotein E3 (APOE ε3). The panels are arranged
as in Fig. 3. Caucasians in several series have twowell-characterized peaks in the S-T15-16 range and the VL-T32-40 range. The Yorubans have a larger proportion
of S toVL poly-Ts connected toAPOE ε3 and a greater proportion of S-T15 alleles thanCaucasians (assay5 /21 base accuracy, but the proportions are different in
these analyses). In the Yorubans, the range of VL alleles extends to the 45-50T range, extremely rare in Caucasians. In the Yorubans S range there are also T19-21
alleles connected toAPOE ε3, also not observed in Caucasians. The African-Americans demonstrate all the alleles carried in Caucasians and Yorubans, particularly
the T19-20 and the T45-50 characteristic of the Yorubans. Again the Japanese demonstrate a “shorter” VL range of 26 to 35 compared with the Caucasians, Yor-
ubans, and the African-Americans. There are a greater proportion of VL to S alleles inAPOE ε3-connected haplotypes in the Japanese, consistent with a later age of
onset of AD in Japanese population who have a higher proportion of the APOE ε3–VL/VL genotypes. Abbreviations: S, short; L, long; VL, very long.
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peaks of poly-Ts linked to the APOE ε4 alleles: a S-T15
allele which is uncommon in Caucasians, the L-T20-23
peak is similar to the shorter of the two L peaks in Cauca-
sians, and only a few longer longs (T30-33) from the pre-
viously defined (in Caucasians) overlap region between L
and VL. The predominant L (T 28–29) peak observed in
Caucasians is conspicuously absent in Yorubans. The
African-American samples (Fig. 3, Panel B) illustrate the
overlapping range of L sizes attached to APOE ε4 strands
from both the Yoruban (T30-33) and Caucasians (T28-29).
Note that the Japanese population only has the predomi-
nant L (T24-28) peak (Fig. 3, Panel C) and, in this rela-
tively small illustrated cohort, excludes the shorter L
(T20-23) of the two L Caucasian peaks previously pub-
lished [1,8,9]. This further illustrates the heterogeneity
between ethnicities with recognizable genetic variations
[5,8].
Fig. 4 represents the histograms for APOE ε3-connected
TOMM40’523 poly-T lengths. Connected to APOE ε3 in the
African-American samples are S lengths, including short
(T14-16) peaks observed frequently in Caucasians, and an
approximately equal number of longer VL lengths of
TOMM40’523. The Yorubans have a predominant S-T16
peak attached to APOE ε3 (Fig. 4, Panel D) compared
with a predominant S-T15 attached to APOE ε4 (Fig. 3,
Panel D and Fig. 1). African-Americans have both sets of
data (Fig. 3 and 4, Panel B).3. Discussion
APOE ε3 is the most common APOE allele in all
populations. TOMM40’523-APOE in-phase haplotypes
are more accurate than simply APOE ε4 alone in Cauca-
sians. We hypothesize that these informative genotypes
(both inherited haplotypes) are generalizable and
predictive in other ethnic populations. Because the APOE
ε4-TOMM40’523 haplotypes contain all the APOE ε4-con-
taining genotypes, the addition of APOE ε3-TOMM40’523
and APOE ε2-TOMM40’523 haplotypes is especially
important in ethnicities with low allele frequencies of
APOE ε4. In Chinese, Korean, and Japanese populations,
the APOE ε4 allele frequency is approximately one third
of Caucasians yet the prevalence of LOAD in the popula-
tions also grows with age with the main genotype being
APOE ε3/3. It is now clear that APOE ε3-TOMM40 haplo-
types do not provide a neutral effect on onset of LOAD, but
map with later age of onset distributions. The literature
frequently considered APOE ε3 as a normal comparator
to APOE ε4 carriage, but only the APOE ε2/2 genotype ap-
pears almost totally preventive.
The joint interaction of the expressed and metabolized
protein products of the APOE and TOMM40 genes, and
possibly other promoters or modifiers within the same LD
region, has supported the hypothesis that both sets of poly-
morphisms contribute to the early, preclinical pathogenesis
of AD, whereas still other interactions may accelerate the
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ological course of the disease [14].
The “missing heritability” of AD can be defined with
fully informed TOMM40’523-APOE haplotypes, derived
from a phylogenetic map and the ability to assess grouping
of TOMM40’523 lengths grouped on the phylogenetic
map [8,9]. Searching the genome with more than two
dozen genome-wide association studies (GWAS) has not
defined “missing heritability”. There have been many gene
hypotheses from GWAS, and imputing the role of SNPs in
noncoding regions near genes, but little successful
translation to drug discovery or development for LOAD.
TOMM40’523-APOE haplotypes account for .98% of the
age-dependent risk of onset. Four of the five SNPs repre-
sented on the commercially available chips as in the
“APOE” LD region are Single nucleotide polymorphisms
SNPs from the TOMM40 gene, yet these data are frequently
interpreted as support only for APOE solely because they are
in LD. Our data would suggest a single structural variation
located in a TOMM40 intron may affect the expression of
TOMM40, APOE, and possibly other nearby genes or struc-
tural variants to influence the metabolism leading to age-
dependent expression of early metabolic imaging studies
and expression of clinical disease [13-15]. It is interesting
to observe the recent interest in “APOE” in the LOAD
scientific field, especially when the data suggests that
another critical gene adjacent to APOE is involved in the
pathogenesis. In fact, the two specific APOE SNPs (at
positions 112 and 152 of 299 amino acids) were not
included on either of the two popular GWAS testing
platforms nor could they alone generate the extremely
high statistical association of the “APOE region.” GWAS
actually tested TOMM40 SNPs and a SNP located in the 30
non-coding region of APOE to generate all the GWAS
data, but haplotypes from this region of LD involving both
the APOE and TOMM40 genes predict the age of onset dis-
tribution better than APOE alone. The poly-T variations at
the TOMM40’523 locus are used to identify haplotypes
associated with specific clades by phylogenetic mapping.
The locations of similar poly-T length variants supports
the hypothesis that much of the hereditability is located at
this highly variant locus. Human triplet repeat diseases
with intra- and intergenerational variability in the length at
a single locus is usual, but this is not the same as the stable
clad-specific inheritance pattern as TOMM40’523. Howev-
er, triplet repeat disease variable lengths specifically affect
the expression of the disease phenotype [16–18].
We hypothesize the likelihood of developing LOAD
among African-Americans is more accurately determined
by consideration of the TOMM40’523-APOE haplotype
than the APOE isoform alone, which is based on Caucasian
data; however we cannot presently test this hypothesis.
Several African-American MCI-AD/LOAD age-of-onset
studies have been initiated, but it will be years before pro-
spective data will be available. Although the current TOM-
MORROW clinical trial permits enrollment of normalAfrican-American subjects, registration will be based on
Caucasian data. Those data are also years away.
Our data supports the hypothesis, derived from the data
of several African-American cohorts in the United States
and two from West Africa, appear to represent a genetic
cross between West Africans and Caucasians. A large pro-
portion of the African-American population carries the
L-TOMM40’523 allele connected to an APOE ε3 allele,
which until now has only been observed in West Africans.
In Caucasians, .98% of the long TOMM40’523 alleles
are connected to APOE ε4. A new S(T 5 15)
TOMM40’523 length allele connected to APOE ε4 is
also characteristic of West African populations and is
observed in the African-Americans in far greater fre-
quency than in Caucasians. The fact that African-
Americans share both sets of L-connected alleles might
explain the higher frequency of AD in this population
than would be expected by APOE ε4 alone [1–7].
Confirmation of the role of these specific inherited poly-
T lengths relative to age of onset will require in-phase as-
says that are more accurate for more exact haplotype calls
in individual subjects.
The analysis of individuals in the African-American
and West African (Yoruban and Ghanaian) population
showed that both of the short TOMM40’523 allele groups
(T 5 15 and T 5 16) are connected to APOE ε3 and
APOE ε4 in approximately equal proportions. Similarly,
in the Yorubans and the African-Americans, there is
connection of APOE ε4 to a S (T15) allele, which is
observed only rarely in Caucasians. Up to now, this large
proportion of APOE ε4 attached to the S (T15) allele has
not been observed in any other population [19]. The pres-
ence of S TOMM40’523 alleles connected to APOE ε4 in
approximately equal proportions to those connected to
APOE ε3 in African-Americans can be explained by
admixture in recent history, where Caucasians contributed
mostly L-T28-29) APOE ε4-TOMM40’523 chromosomes
and West Africans contributed the L-T30-32) chromo-
somes. The connection of either short T15 or T16 to
APOE ε4 in Caucasians is extremely uncommon in all
cohorts studied to date. This highlights the importance
of looking at an individual’s ancestry. As was demon-
strated using two new independently performed poly-T
assay methods, the S-APOE ε4-haplotype is inherited
from the Yorubans has a specific and slightly different
number of S-T15 poly-Ts in this genomic region. This
strongly supports the proposition that a cross-over muta-
tion occurred in the West African population, that is not
observed in Caucasians. We have no data to implicate
whether the S-T15 allele affects the age of onset distribu-
tion of APOE ε4 differently, but his can now be tested in
prospective age of onset study. However, this haplotype
was transferred to the African-Americans from West Afri-
can ancestors.
At the time of the earlier Ghanaian experiments, the
accuracy of the original assay was within 62 Ts. It was
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genomic region (Polymorphic DNA Technologies, Inc; see
Supplementary Methods) was developed that it became
possible to differentiate the S-T15 peak from the S-T16
peak, and linkage of S-T15 to APOE ε4 in the West Africans
and, subsequently, in the African-Americans. Simply put,
the African-American samples represent a mixture of the
characteristic TOMM40-APOE haplotypes in both West
African Yorubans (APOE ε4 and APOE ε3 short) and Cau-
casians (only APOE ε4). Before assays for the continuity
of TOMM40’523 and APOE were possible, APOE ε4 mea-
surements in African-Americans underestimated the L-
TOMM40’523 allele because the haplotype S15-L had not
been encountered previously attached to APOE ε4. Because
a significant proportion of APOE ε3/4 patients could be ho-
mozygous for APOE ε4, underestimating the S-APOE ε4 ho-
mozygous effect simply using the S classification in the
context of the APOE ε3/3 and APOE ε3/4 subject groups.
Similarly it would skew interpretations of S/S homozygotes
and each of the other categories. The situation is straightfor-
ward: the TOMM40’523-APOE haplotypes used for age of
onset stratification for African-Americans would be more
accurate if all of the TOMM40’523-APOE haplotypes
were incorporated. An algorithm for predicting high risk
African-American individuals to enter a prevention trial
would be based on all of the African-American haplotypes
instead of using the original Caucasian poly-T length-based
claasification of the risk algorithm.
One must be careful defining “African-American” popu-
lations based on a social nomenclature. In fact, Africans who
may have emigrated fromAfrica recently, with no Caucasian
genetic interactions, can be characterized socially as
African-Americans when they simply reside in the United
States. In other countries where immigration is common,
African-Americans are referred to with different social
classifications, and are not defined genetically. African-
Caribbean is a commonly used classification in the UK.
Due to diffuse migration patterns, scientists should be very
careful to avoid expectations that social classifications
reflect the specific genetic heritage in all cases. Geographic
relationships among these groups may be more powerful
than any social classification. For example, in a previously
reported Caucasian series from Canada, two individuals
were observed to carry a S poly-T length linked to APOE
ε4 [8]. In that study, L was reported as “98%” attached to
APOE ε4 strands, but was later observed to be 100% in
several other dispersed Caucasian analyses, including the
Arizona series in the discovery study and Caucasian cohorts
from Tomsk, Siberia, and Russian immigrants to Israel.
Thus, it is possible that those two Canadian individuals
will have had African ancestors but still self-reported as
Causasian [19].
The presence of S TOMM40’523 alleles connected to
APOE ε4 in approximately equal proportions to those con-
nected to APOE ε3 in African-Americans can be explained
by admixture in recent history, where Caucasians contrib-uted mostly long (T 28–29) APOE ε4-TOMM40’523 chro-
mosome and West Africans contributed the long (T 30–32)
chromosomes that could have been characterized as VL us-
ing the Caucasian-based convention. The connection of
either S-T15 or S-T16 to APOE ε4 in Caucasians is
extremely uncommon in all cohorts studied to date. This
highlights the importance of looking at an individual’s
ancestry in studied populations. As was demonstrated
using two new performed poly-T assay methods (see
Supplementary Methods), the S-TOMM40’523-APOE ε4
haplotype inherited from the Yorubans has a specific and
slightly different number of S15 poly-Ts in this genomic re-
gion. This strongly supports the proposition that a cross-over
event occurred in the West African population, that was not
observed in Caucasians.3.1. Possible role of TOMM40 in mitochondria and
metabolism
TOMM40 encodes the principle mitochondrial protein
import pore, and is therefore critically important for mito-
chondrial biogenesis and function [20]. Research is under-
way in African-American AD subjects and normal controls
to determine how accurately the APOE genotype or the spe-
cific TOMM40 genotype describes the major susceptibility
influence for LOAD, or whether both interact and may
contribute to the pathogenesis in mitochondria leading to
characteristic neuronal death and neuropathology [21,22].
APOE fragments generated within neurons may affect
mitochondrial dynamic functions [23,24]. If this role is
verified, this could also explain both the early and long-
term effects of APOE genotypes on glucose utilization
observed using PET glucose and/or BOLD oxygen con-
sumption models [25–31]. It is critically important to note
that the conclusions of such age-related metabolic imaging
studies, especially positron emission tomography (PET) im-
aging, demonstrate life-long neuroanatomically consistent
regional decreased glucose utilization related to APOE ge-
notypes [32]. All the DNA samples from these previous
studies could be analyzed, if they were available and had
been consented properly in the past, so that the imaging
studies could be related to specific TOMM40’523 geno-
types. Our hypothesis would be that the long allele lengths
depict the genetic risk of the neuronal degeneration leading
to the later manifestations of the disease pathogenesis,
including the amyloid cascade, tau deposition, atrophy,
and the tragic clinical disease.
The mechanism by which TOMM40’523-APOE haplo-
type variation affects mitochondrial structure and function
will require extensive research. It is generally proposed
that structural DNAmutations can exert their effects through
transcriptional and post-translational maturation and pro-
cessing, which can result in differences in alternative
splicing or protein expression. Recently, we demonstrated
that TOMM40’523 affects the expression of APOE and
TOMM40 mRNAs in brain tissues (temporal and occipital
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affect of this poly-T variation on transcription regulation
was supported in a cell-based luciferase reporting system
[12]. The number of protein import channels per mitochon-
drion may be regulated by TOMM40’523 variations. The
downstream effects may appear over a comparatively long
time span (lifespan) and be associated with other environ-
mental factors. With neuronal diseases affecting mitochon-
dria, it should be recalled that neurons receive their initial
complement of mitochondria maternally, and the life spans
of these mitochondria are limited to the reproductive effi-
ciency of these mitochondria. Unlike most other tissues in
the body, the brain has little cellular capacity to replace mito-
chondria damaged by ROS generated by the high rates of
glucose combustion, compared with dividing cells in other
tissues, so the reproductive capacity and dynamics of
neuronal mitochondria is a critical factor in determining
neuronal health.
Consistent with this hypothesis, the TOMMORROW
clinical trial now in-progress will test whether a drug that
increases glucose and oxygen metabolism by increasing
mitochondrial function and number can delay the onset
of MCI-AD in those subjects of highest risk for onset
within the five years of the study [9]. From an exploratory
viewpoint, the data derived from this large population-
based study may provide extensive evidence for the role
of TOMM40’523 variants in the presentation and progres-
sion of MCI to LOAD clinical signs and symptoms
[11,33,34].
It is also reasonable to expect that TOMM40’523 variants
may involve mitochondria in the pathogenesis of other
neurodegenerative and neuropsychiatric diseases. The rela-
tionship of other aggregating peptides, such as a-synuclein,
may affect mitochondrial dynamics and select other specific
neuronal cell types characteristic of other neurodegenerative
diseases [35–40]. Clearly there is value in investigating the
participation of other molecules, like synuclein and TDP-
43 (transactive response DNA-binding protein 43, for mito-
chondrial interactions in neuronal cells specifically affected
in other neuropathologically defined diseases [39,40]).
Similar neuronal mitochondrial mechanisms processes
may also underlie other neurodegenerative and metabolic
diseases. The coexistence of multiple disease-associated pa-
thologies in AD, Parkinson’s disease, fronto-temporal de-
mentia, amyotrophic lateral sclerosis and other diseases
may stimulate new discoveries and insights into early
pathogenesis for focused targets for discovery and drug
development.
The genetic association of a GGGGCC (G4C2) hexanu-
cleotide repeat expansion in the chromosome 9 open
reading frame 72 (C9ORF72) gene is a common cause
of amyotrophic lateral sclerosis and frontotemporal de-
mentia should be also be investigated genetically
using phylogenetic analysis to identify specific
haplotype sharing and translational downstream mecha-
nisms [41–44].RESEARCH IN CONTEXT
1. Systematic Review: Allele frequency data for
TOMM40’523 poly-T lengths have been replicated us-
ing three new assays. The current assays used for this
research are each accurate to6 1 T. One of the new as-
says is an in-phase assay that allows chromosome
strand-specific haplotypes to bedetermined accurately,
without an imputation step based on Caucasian poly-T
lengths, especially clarifying the haplotypes in the re-
gion of long (L) and very long (VL) overlap.
2. Interpretation: In the Yorubans there has been a
cross-over mutation leading to a new haplotype.
This haplotype combines apolipoprotein E4 (APOE
ε4) with a Short-T15 allele, and represents many of
the APOE ε4 containing haplotypes in Ghanaian
and Nigerian Yoruban inheritance. Thus the APOE
ε4 allele frequency is attached to a new S-T15
TOMM40’523 allele but there are no age of onset
data for the new haplotype.
3. Future directions: African-Americans carry both
Caucasian-specific sizes linked to APOE ε4, and S-
T15- APOE ε4, as well as slightly larger sized
APOE ε4 alleles in TOMM40’523-haplotypes. This
is evidence of genetic admixture between West Afri-
cans and Caucasians.References
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Clinical data sets
The Ghanaian, Japanese, and original African-American
samples were published previously [12]. The population
controls of African-Americans and Yoruban samples were
purchased from Coriell Cell Repositories (Camden, NJ),
and are independent of the previously published collections
referred to above and cohorts published in the original
TOMM40’523 (Translocase of Outer Mitochondria Mem-
brane) report. [8]
(A) APOE Genotyping (Polymorphic DNA Technologies,
Inc)
Apolipoprotein E (APOE) genotyping was performed at
polymorphic DNATechnologies, (Alameda, CA). Two Sin-
gle nucleotide polymorphisms SNPs (dbSNP ID rs429358
and rs7412) within the gene APOE were genotyped by the
method of amplicon sequencing using “nested” PCR fol-
lowed by automated Sanger sequencing. For each SNP, hu-
man genomic DNA samples were first PCR-amplified with
a pair of “outside” oligonucleotide primers, and those ampli-
fication products were then reamplified with a second pair of
“inside” primers. Final PCR products were cleaned to re-
move small products and then sequenced using ABI Big
Dye chemistry with detection and analysis on an ABI3730xl
DNA sequencer. Forward and reverse electropherograms
were processed by sequence analysis software that made
alignments against the known reference sequences, and the
genotype calls were taken from the base-calls at the known
SNP sites.
(B) TOMM40’523 poly-T Genotyping, method 1
(Polymorphic DNA Technologies, Inc)
A variable length poly-T (dbSNP ID rs10524523) within
the gene TOMM40 was genotyped [45]. The method ex-
ploits the fact that during cycle-sequencing reactions of short
amplicons, Taq DNA polymerase adds fluorescent 30-deoxy-
adenosine tags to full-length primer extension products that
can be detected and used as a measure of total amplicon
length. Two different assays (Assay 1 and Assay 2) were
used, each using a different set of primers. A nested PCR
was performed for each assay using the same conditions
described above for APOE genotyping. After the second
PCR step, an internal standard (containing an amplicon
with the artificial allele poly(T)8) was added to the product.
A Sanger sequencing reaction was performed for each assay
using only the forward primer as the sequencing primer, and
fluorescent products were detected with an ABI 3730xl DNA
sequencer. Because of PCR “stutter” of the poly-T sequence,
a complex pattern of terminal A-peaks was seen. Proprietary
software was used to identify and assign allele lengths to the
A-peaks in the complex pattern, and to deduce the allele
lengths present in the original genomic sample. Final geno-
types were reported as the allele averages of the two assays.(C) TOMM40’523 poly-T length analysis, Method 2 (Dr
Dmitry Goldgaber)
To analyze the precise length of the poly-T stretch of the
rs10524523 polymorphic site of the TOMM40 gene PCR
was performed using 50- fluorescently labeled forward
primer ACCTCAAGCTGTCCTCTTGC and unlabeled
reverse primer GAGGCTGAGAAGGGAGGATT each at
0.5 mMconcentration. The coordinates of the amplified frag-
ment were chr19:500948191 50094997 (NCBI36/hg18 hu-
man genome assembly). The PCR reaction was performed in
20ml volumes with FailSafe PCR kit (Epicentre Biotechnol-
ogies, Madison, WI) using buffer G. The PCR reaction was
carried under the following conditions: 3 minutes at 95C,
40 seconds at 98C, then 10 cycles with 30 seconds at
95C, 90 seconds at 63C, then 18 cycles with 30 seconds
at 95C, 1 minute at 61C, then final extension 7 minutes
at 72C. One microliter of each PCR product was diluted
with 15 ml of HiDi Formamide (Applied Biosystems, Foster
City, CA) and supplemented with 0.3 ml of 600LIZ size stan-
dard (Applied Biosystems, Foster City, CA). The size of
PCR products was determined by electrophoresis using an
ABI 3730 DNA analyzer (Applied Biosystems, Foster
City, CA) at the Cornell University Genomics Core Labora-
tory (Ithaca, NY). The output data from the ABI 3730 were
analyzed using GeneMarker software (SoftGenetics, State
College, PA). The presence of the poly-T stretch caused
“stuttering” of DNA polymerase during PCR resulting in
generation of PCR products of various lengths that appeared
as a staggered peak [45]. To interpret these complex peak
patterns we generated DNA fragments with known number
of T residues by subcloning individual rs10524523-
containing DNA fragments that were amplified from several
human genomic DNA samples. Each resulting plasmid DNA
was Sanger sequenced and the length of poly-T was pre-
cisely determined. Thus a series of individual plasmid
DNA samples with known number of T residues in the
poly-T stretch was generated. Plasmid DNAwas PCR ampli-
fied along with tested human DNA samples in each analysis.
The resulting peaks from plasmid DNAwas compared with
peaks generated from human DNA samples.
(D) Phased Sequencing of a 9.5 kb TOMM40/APOE
genomic region (Polymorphic DNA Technologies, Inc),
Method 3
For selected genomic samples in this study, the haplotype
phases between the APOE SNPs and the TOMM40’523
poly-T were determined by the method of long-range PCR,
DNA cloning into plasmids, and Sanger sequencing. Long-
range PCR was performed using Takara LATaq Polymerase
(Takara Mirus Bio, Mountain View, CA) and very long cycle
times to create a 9.5 kb amplicon that contained both the
TOMM40 poly-T region and the APOE SNPs rs429358
and rs7412. This amplicon was purified by agarose gel elec-
trophoresis and cloned into a TA cloning vector (TOPO XL
PCR, Life Technologies, Inc.). The vector was then used to
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were plated with antibiotic selection, incubated, and 12 col-
onies were picked from each plate and cultured. Diluted cul-
tures were transferred to a denaturing buffer and were
prepped using a TempliPhi DNA Sequencing Template
Amplification kit (GE HealthCare/Amersham Biosciences,
Pittsburgh, PA). For each original sample, twelve plasmid
templates were then used in Sanger sequencing reactions us-
ing sequencing primers having sites within the cloned region.Because only the phases of the poly-Twith the APOE SNPs
were needed, only the 800 bp at each end of the 9.5 kb insert
were sequenced. A sequencing alignment report was made
for each clone of each sample. For each sample, two
sequencing patterns were seen, with some clones giving
the sequence of one haplotype and the other clones giving
the sequence of the other haplotype. The consensus se-
quences for each haplotype were used directly to report the
phases of the poly-T alleles with the APOE alleles.
